We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+6.78%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$150M
AUM Growth
-$10.7M
Cap. Flow
-$11.4M
Cap. Flow %
-7.61%
Top 10 Hldgs %
46.24%
Holding
65
New
12
Increased
10
Reduced
12
Closed
16

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$3.24M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$3.07M
3
OCUL icon
Ocular Therapeutix
OCUL
+$2.58M
4
MGNX icon
MacroGenics
MGNX
+$2.53M
5
NGNE icon
Neurogene
NGNE
+$2.34M

Top Sells

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$5.29M
2
ASRT
Assertio
ASRT
+$4.53M
3
GERN icon
Geron
GERN
+$3.87M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$3.38M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$2.91M

Sector Composition

Rank Sector Weight
1 Healthcare 91.89%
2 Miscellaneous 8.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AXGN icon
1
Axogen
AXGN
$2.78B
$14.6M 9.74%
2,120,000
– –
GNMX
2
DELISTED
Aevi Genomic Medicine Inc
GNMX
$10.8M 7.23%
1,950,000
+392,300
+25% +$2.06M
ARIA
3
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$9.24M 6.17%
1,250,000
– –
KYNB
4
Kyntra Bio
KYNB
$32.4M
$5.42M 3.62%
13,200
+200
+2% +$91.6K
BPMC
5
DELISTED
Blueprint Medicines
BPMC
$5.06M 3.38%
250,000
+30,000
+14% +$545K
HROW icon
6
Harrow
HROW
$1.44B
$4.77M 3.18%
1,267,500
+17,500
+1% +$68.2K
CDXS icon
7
Codexis
CDXS
$182M
$4.75M 3.17%
1,178,500
– –
ADMS
8
DELISTED
Adamas Pharmaceuticals
ADMS
$4.54M 3.03%
300,000
-20,000
-6% -$330K
FOMX
9
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$4.41M 2.95%
695,000
+105,000
+18% +$697K
TVRD
10
Tvardi Therapeutics
TVRD
$24M
$4.02M 2.68%
23,194
-556
-2% -$121K
AMRN
11
Amarin Corp
AMRN
$297M
$3.8M 2.54%
88,000
– –
AGIO icon
12
Agios Pharmaceuticals
AGIO
$2.05B
$3.56M 2.38%
85,000
-20,000
-19% -$988K
HZNP
13
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.29M 2.2%
+200,000
New +$3.24M
RARE icon
14
Ultragenyx Pharmaceutical
RARE
$2.59B
$3.18M 2.12%
65,000
-45,000
-41% -$2.91M
MGNX icon
15
MacroGenics
MGNX
$260M
$3.02M 2.02%
+112,000
New +$2.53M
IMMU
16
DELISTED
Immunomedics Inc
IMMU
$3.02M 2.01%
1,300,000
-25,000
-2% -$83.5K
INDP icon
17
Indaptus Therapeutics
INDP
$155M
$2.99M 2%
290
+5
+2% +$44.9K
AMAG
18
DELISTED
AMAG Pharmaceuticals
AMAG
$2.87M 1.92%
120,000
-100,000
-45% -$2.29M
CMRX
19
DELISTED
Chimerix, Inc.
CMRX
$2.65M 1.77%
675,000
– –
SUPN icon
20
Supernus Pharmaceuticals
SUPN
$2.57B
$2.55M 1.7%
125,000
– –
GBT
21
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.52M 1.68%
+152,000
New +$3.07M
XENE icon
22
Xenon Pharmaceuticals
XENE
$6B
$2.42M 1.62%
410,000
+10,000
+3% +$68.6K
PDSB icon
23
PDS Biotechnology
PDSB
$12.2M
$2.28M 1.52%
11,280
+2,030
+22% +$359K
IOVA icon
24
Iovance Biotherapeutics
IOVA
$3.74B
$2.11M 1.41%
+260,000
New +$1.63M
CYNA
25
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$2.09M 1.4%
125,000
+4,000
+3% +$53.8K
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2016 Portfolio in Review

As of Q2 2016, Opaleye Management held 65 positions worth $150M, down 6.6% from $160M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Opaleye Management withdrew a net $11.4M in Q2 2016, closing 16 positions and reducing 12 holdings. Its most notable exit was Sage Therapeutics, an estimated $5.29M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 88% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $3.29M.

  • Opaleye Management's largest Q2 2016 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 200,000 shares worth $3.29M.
  • Opaleye Management added most to Aevi Genomic Medicine Inc in Q2 2016, an estimated $2.06M increase.
  • Opaleye Management's biggest Q2 2016 reduction was Ultragenyx Pharmaceutical, cutting an estimated $2.91M.
  • Opaleye Management fully exited Sage Therapeutics in Q2 2016, selling an estimated $5.29M.
  • Opaleye Management's ten largest holdings make up 46% of its $150M portfolio in Q2 2016.
  • Opaleye Management opened 12 new positions and closed 16 in Q2 2016.
  • Opaleye Management's portfolio value fell 6.6% quarter-over-quarter to $150M.

Based on Opaleye Management's 13F filing for Q2 2016, filed 12 Aug 2016.